180 related articles for article (PubMed ID: 34649623)
1. 3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation.
Skaripa-Koukelli I; Hauton D; Walsby-Tickle J; Thomas E; Owen J; Lakshminarayanan A; Able S; McCullagh J; Carlisle RC; Vallis KA
Cancer Metab; 2021 Oct; 9(1):37. PubMed ID: 34649623
[TBL] [Abstract][Full Text] [Related]
2. MCT1, MCT4 and CD147 expression and 3-bromopyruvate toxicity in colorectal cancer cells are modulated by the extracellular conditions.
Pereira-Vieira J; Azevedo-Silva J; Preto A; Casal M; Queirós O
Biol Chem; 2019 May; 400(6):787-799. PubMed ID: 30699066
[TBL] [Abstract][Full Text] [Related]
3. 3-Bromopyruvate treatment induces alterations of metabolic and stress-related pathways in glioblastoma cells.
Chiasserini D; Davidescu M; Orvietani PL; Susta F; Macchioni L; Petricciuolo M; Castigli E; Roberti R; Binaglia L; Corazzi L
J Proteomics; 2017 Jan; 152():329-338. PubMed ID: 27890797
[TBL] [Abstract][Full Text] [Related]
4. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression.
Sanità P; Capulli M; Teti A; Galatioto GP; Vicentini C; Chiarugi P; Bologna M; Angelucci A
BMC Cancer; 2014 Mar; 14():154. PubMed ID: 24597899
[TBL] [Abstract][Full Text] [Related]
5. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
6. Combination of 3PO analog PFK15 and siPFKL efficiently suppresses the migration, colony formation ability, and PFK-1 activity of triple-negative breast cancers by reducing the glycolysis.
Kashyap A; Umar SM; Dev J R A; Mathur SR; Gogia A; Batra A; Deo SVS; Prasad CP
J Cell Biochem; 2023 Sep; 124(9):1259-1272. PubMed ID: 37450687
[TBL] [Abstract][Full Text] [Related]
7. Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.
El Sayed SM; Mohamed WG; Seddik MA; Ahmed AS; Mahmoud AG; Amer WH; Helmy Nabo MM; Hamed AR; Ahmed NS; Abd-Allah AA
Chin J Cancer; 2014 Jul; 33(7):356-64. PubMed ID: 24636230
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
[TBL] [Abstract][Full Text] [Related]
9. 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.
El Sayed SM; El-Magd RM; Shishido Y; Chung SP; Diem TH; Sakai T; Watanabe H; Kagami S; Fukui K
J Bioenerg Biomembr; 2012 Feb; 44(1):61-79. PubMed ID: 22318356
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
[TBL] [Abstract][Full Text] [Related]
11. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
[TBL] [Abstract][Full Text] [Related]
12. Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation.
Bartmann C; Janaki Raman SR; Flöter J; Schulze A; Bahlke K; Willingstorfer J; Strunz M; Wöckel A; Klement RJ; Kapp M; Djuzenova CS; Otto C; Kämmerer U
Cancer Metab; 2018; 6():8. PubMed ID: 29942509
[TBL] [Abstract][Full Text] [Related]
13. The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors.
Muller C; Lacroix-Malgras V; Kluza J; Laine W; Güler Y; Bost F; Boisbrun M; Mazerbourg S; Flament S
Cancer Cell Int; 2024 Apr; 24(1):132. PubMed ID: 38594745
[TBL] [Abstract][Full Text] [Related]
14. MCT1 in Invasive Ductal Carcinoma: Monocarboxylate Metabolism and Aggressive Breast Cancer.
Johnson JM; Cotzia P; Fratamico R; Mikkilineni L; Chen J; Colombo D; Mollaee M; Whitaker-Menezes D; Domingo-Vidal M; Lin Z; Zhan T; Tuluc M; Palazzo J; Birbe RC; Martinez-Outschoorn UE
Front Cell Dev Biol; 2017; 5():27. PubMed ID: 28421181
[No Abstract] [Full Text] [Related]
15. Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer.
Romero-Cordoba SL; Rodriguez-Cuevas S; Bautista-Pina V; Maffuz-Aziz A; D'Ippolito E; Cosentino G; Baroni S; Iorio MV; Hidalgo-Miranda A
Sci Rep; 2018 Aug; 8(1):12252. PubMed ID: 30115973
[TBL] [Abstract][Full Text] [Related]
16. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate.
Queirós O; Preto A; Pacheco A; Pinheiro C; Azevedo-Silva J; Moreira R; Pedro M; Ko YH; Pedersen PL; Baltazar F; Casal M
J Bioenerg Biomembr; 2012 Feb; 44(1):141-53. PubMed ID: 22350013
[TBL] [Abstract][Full Text] [Related]
17. 3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau.
Ko YH; Niedźwiecka K; Casal M; Pedersen PL; Ułaszewski S
Yeast; 2019 Apr; 36(4):211-221. PubMed ID: 30462852
[TBL] [Abstract][Full Text] [Related]
18. [The effect of downregulation of MCT1 on the proliferation of glioma cells].
Zhou HG; Zhang JD; Zhang YF
Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):208-213. PubMed ID: 30917457
[No Abstract] [Full Text] [Related]
19. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1.
Rincon-Torroella J; Molin MD; Mog B; Han G; Watson E; Wyhs N; Ishiyama S; Ahmedna T; Minn I; Azad NS; Bettegowda C; Papadopoulos N; Kinzler KW; Zhou S; Vogelstein B; Gabrielson K; Sur S
bioRxiv; 2023 Jul; ():. PubMed ID: 37546808
[TBL] [Abstract][Full Text] [Related]
20. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
